Dividends & Buybacks ·
On August 5, 2026, shareholders of 60 Degrees Pharmaceuticals, Inc. approved a reverse stock split with a ratio…
SXTPW60 Degrees Pharmaceuticals, Inc.
On August 5, 2026, shareholders of 60 Degrees Pharmaceuticals, Inc. approved a reverse stock split with a ratio ranging from 1-for-5 to 1-for-10, as determined by the Board in its sole discretion. The company also increased shares available under its 2022 Equity Incentive Plan by 800,000 and ratified RBSM LLP as auditor. Additionally, shareholders approved a management success fee of 5% to 6% of deal proceeds for transactions involving Arakoda. All five directors were re-elected with majority support. The company operates in the pharmaceutical industry.